83 results about "Moderate to severe" patented technology

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl / sufentanil is provided as a water soluble salt (e.g., fentanyl hydrochloride), preferably in a hydrogel formulation, for use in an electrotransport device (10). In accordance with the present invention, a transdermal electrotransport delivered dose of fentanyl / sufentanil is provided which is sufficient to induce analgesia in (e.g., adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.

The present invention relates to pharmaceutical formulations of ibuprofen, oxycodone and 14-hydroxycodeinone and their use for the treatment of acute, moderate to severe pain.

The invention relates to a mitral heart valve prosthesis and a delivery catheter to carry and deploy such a prosthesis. The invention allows to effectively treat a pathology related to moderate to severe mitral regurgitation. Such a prosthesis implantable by catheterism includes mainly a docking station and a leaflet cooperating with the docking station. The leaflet is advantageously arranged in a configuration close to a posterior leaflet of a native mitral valve of a patient.

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl / sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (10). In accordance with one aspect of the invention, the concentration of fentanyl / sufentanil in the donor reservoir (26) solution is above a predetermined minimum concentration, whereby the transdermal electrotransport flux of fentanyl / sufentanil is maintained independent of the concentration of fentanyl / sufentanil in solution. In accordance with a second aspect of the present invention, the donor reservoir (26) of the electrotransport delivery device (10) is comprised of silver and the donor reservoir (26) contains a predetermined “excess” loading of fentanyl / sufentanil halide to prevent silver ion migration with attendant skin discoloration. In accordance with a third aspect of the present invention, a transdermal electrotransport delivered dose of fentanyl / sufentanil is provided which is sufficient to induce analgesia in (eg, adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.

The invention relates to an injectable crosslinked hyaluronic acid gel and a preparation method thereof. The injectable crosslinked hyaluronic acid gel is prepared by blending hyaluronic acid gel granules and chlorinated sodium phosphate physiological buffer solution; the hyaluronic acid gel granules are prepared by comprising the steps of crosslinking treatment, emulsion crosslinking granulation, purification and drying and swelling, filling and sterilization technologies. The hyaluronic acid gel granules are uniform in granule size, the residual of the crosslinking agent is less than 0.2ppm, the injection pushing is proper, and the in-vivo degradation time can last more than 8-12 months. The implant has an excellent esthetical restoration effect, is applicable to being injected to and subcutaneous dermis deep layer to subcutaneous superficial layer, restoration of moderate to severe wrinkles or folds, and can satisfy the restoration demand of wrinkles or folds caused due to skin aging.

The present invention is directed to methods and compositions for inducing, promoting or otherwise facilitating pain relief. More particularly the present invention discloses the combination of a nitric oxide donor and an opioid analgesic in the therapeutic management of vertebrate animals including humans, for the prevention or alleviation of pain, particularly moderate to severe pain. In particular, the nitric oxide donor is a slow-release nitric oxide donor or is formulated to provide a sustained release of a low dose of nitric oxide.

A date palm seed lost circulation material (LCM) is provided having a date palm seed admixture of date palm seed particles of various sizes. The date palm seed particles may have a size greater than about 2380 microns in a range of about 40% to about 42% by weight, particles having a size greater than about 595 microns and less than about 2381 microns in a range of about 46% to about 48% by weight, particles having a size greater than about 400 microns and less than about 596 microns in a range of about 4% to about 6% by weight, particles having a size less than about 210 microns in a range of about 4% to about 6% by weight, and particles having a size less than about 149 microns in a range of about 1% to about 3% by weight. Methods of lost circulation control using and manufacture of a date palm seed LCM are also provided.

Embodiments of the invention can provide systems and methods for analyzing and assessing dementia and dementia-type disorders by integrating the use of electroencephalography (EEG), neuropsychological or cognitive testing data, and cardiovascular risk factor data. Embodiments of the invention can provide systems and methods for early detection of dementia, including Alzheimer's disease (AD), vascular dementia (VAD), mixed dementia (AD and VAD), MCI, and other dementia-type disorders. Embodiments of the invention can provide some or all of the following improvements over conventional systems and methods, including: (1) Increased sensitivity, specificity, and overall accuracy; (2) Detection of AD, VAD and mixed dementia; and (3) Accurate detection of mild dementia and some cases of mild cognitive impairment in addition to the detection of moderate to severe dementia.

Provided herein are methods of detecting and staging liver fibrosis in an individual with liver disease. Also provided are methods of detecting necroinflammatory activity. Invention methods utilize four serum markers, age, and gender to determine an end value. The end value is compared to a cut-off value, in order to identify significant fibrosis (METAVIR stages F2 to F4), or an absence of advanced fibrosis (stages F3 and F4) or cirrhosis (stage F4). In particular aspects, progression or treatment of liver fibrosis can be monitored by invention methods. The end value is also used to distinguish between no to mild necroinflammatory activity (METAVIR grade A0 to A1) and moderate to severe necroinflammatory activity (grade A2 to A3).

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl / sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (10). In accordance with one aspect of the invention, the concentration of fentanyl / sufentanil in the donor reservoir (26) solution is above a predetermined minimum concentration, whereby the transdermal electrotransport flux of fentanyl / sufentanil is maintained independent of the concentration of fentanyl / sufentanil in solution. In accordance with a second aspect of the present invention, the donor reservoir (26) of the electrotransport delivery device (10) is comprised of silver and the donor reservoir (26) contains a predetermined “excess” loading of fentanyl / sufentanil halide to prevent silver ion migration with attendant skin discoloration. In accordance with a third aspect of the present invention, a transdermal electrotransport delivered dose of fentanyl / sufentanil is provided which is sufficient to induce analgesia in (eg, adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.

The invention discloses a memantine hydrochloride capsule sustained-release preparation, wherein the preparation is composed of two parts, namely, immediate-release grains and sustained-release grains; the sustained-release part is composed of a blank pellet core, a medicine layer and a release control layer; and the immediate-release part is composed of a blank pellet core and a medicine layer. The capsule is uniform in content, good in release effect, stable in blood concentration, good for reducing the toxic and side effects of medicines, and is capable of being used for treating moderate-to-severe Alzheimer-type dementia, and the medicine-taking times of the patient are reduced,.

The invention relates to an injectable implant and a preparation method thereof. The implant is amnion microparticles mixed in a sodium chloride phosphate physiological solution with a pH of 7.0-7.5. The preparation method comprises the following steps of disinfection processing, decellularization processing, modification processing, and amnion microparticle preparation, and in particular, comprises: taking amnion microparticles as a component A and a sodium chloride phosphate physiological solution as a component B, performing vibration and well mixing according to a mass volume ratio of 20:1-100:1 to prepare an amnion microparticle suspension with a concentration of 20-100 mg / mL by high-speed microjet equipment, wherein the particle size of the amnion microparticles is 50-200 microns. The injectable implant of the invention maintains the natural three dimensional stereo structure and a lot of natural active components of human amnion, reduces immunological rejection reaction caused by raw material source after clinical application of cosmetic injection products, is suitable for injection into deep subcutaneous dermal layer to subcutaneous superficial layer to repair moderate to severe wrinkles or folds, and has good cosmetic repair effect.

Embodiments of the invention can provide systems and methods for anaiyzing and assessing dementia and dementia-type disorders by integrating the use of electroencephalography (EEG), neuropsychological or cognitive testing data, and cardiovascular risk factor data. Embodiments of the invention can provide systems and methods for early detection of dementia, including Alzheimer's disease (AD), vascular dementia (VAD), mixed dementia (AD and VAD), MCI, and other dementia-type disorders. Embodiments of the invention can provide some or all of the following improvements over conventional systems and methods, including: (1) Increased sensitivity, specificity, and overall accuracy; (2) Detection of AD, VAD and mixed dementia; and (3) Accurate detection of mild dementia and some cases of mild cognitive impairment in addition to the detection of moderate to severe dementia.

This invention refers to the pharmaceutical combinations of Ketorolac salts and B-complex; to the methods used to make said combinations; and particularly, to ketorolac and B-complex synergic combinations useful in the treatment of patients that suffer from moderate to severe pain and neuralgias in different body sites.

This invention relates to an effective dietary intervention plan. In one aspect all food is withheld for a period of at least 5 days, except for tropical root crops. In another aspect the invention relates to the treatment of various symptoms, conditions or diseases such as Diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension, and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to extensive and moderate to severe symptoms due to food allergies, sensitivities, and intolerances, bloating, pain, headaches, leaky gut, hyperactivity, sleeping difficulties, severe underweight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid reflux, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms, seizures by withholding from the patient for a period of at least 5 days all food except for concentrated forms of concentrated tropical root crops. Preferably the patient is also removed from external environmental sources of allergens. After the initial withholding period new foods may be introduced according to a particular selection and schedule. In another aspect of the invention the subject undergoes an effective dietary intervention plan in which at least five (5) tropical root crops are selected, each eaten on a successive day, along with selected other meat, vegetables, and oils that the subject has never eaten before, eating a different selection of meat, vegetables, and oils each from different food families each day, with no food or food family being repeated for at least 5 days. In another aspect the invention relates to the treatment of various symptoms, conditions or diseases such as Diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension, and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to extensive and moderate to severe symptoms due to food allergies, sensitivities, and intolerances, bloating, pain, headaches, leaky gut, hyperactivity, sleeping difficulties, severe underweight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid reflux, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms, seizures by withholding from the patient for a period of at least 5 days all food except for concentrated forms of concentrated tropical root crops. Preferably the patient is also removed from external environmental sources of allergens. After the initial withholding period new foods may be introduced according to a particular selection and schedule. In another aspect of the invention the subject undergoes an effective dietary intervention plan in which at least seven (7) tropical root crops are selected, each eaten on a successive day, along with selected other meat, vegetables, and oils that the subject has never eaten before, eating a different selection of meat, vegetables, and oils each from different food families each day, with no food or food family being repeated for at least 7 days. In another aspect the invention relates to the treatment of various symptoms, conditions or diseases such as Diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension, and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to extensive and moderate to severe symptoms due to food allergies, sensitivities, and intolerances, bloating, pain, headaches, leaky gut, hyperactivity, sleeping difficulties, severe underweight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid reflux, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms, seizures by withholding from the patient for a period of at least 5 days all food except for concentrated forms of concentrated tropical root crops. Preferably the patient is also remo

Hemostatic devices and methods of making same are disclosed. Disclosed hemostatic devices include biocompatible non-oxidized regenerated cellulose. The disclosed hemostatic devices are effective in providing and maintaining hemostasis in cases of moderate to severe bleeding caused by non-compressional and / or non-tourniquetable injuries, among other things. The disclosed methods enable manufacture of a bioabsorbable, biocompatible, biodegradable carboxylmethyl cellulose having high stability and high adherence.

Embodiments of the invention relate to compositions and methods of dry eye or keratoconjunctivitis sicca.

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody.

Ketorolac tromethamine is a new type of non-steroidal analgesic and anti-inflammatory drug with strong analgesic effect, which can be administered orally or by injection. It is mainly used to relieve moderate to severe postoperative pain, and Acute renal colic related to trauma, visceral pain related to cancer, anti-inflammatory of local inflammation, etc., the present invention provides a preparation method of ketorolac tromethamine freeze-dried powder preparation, which greatly improves the stability of the main drug, It not only overcomes the shortcoming of slow onset of oral administration, but more importantly, overcomes the problems of unstable main drug of liquid injection and unstable process in actual production.

A date tree fiber mix lost circulation material (LCM) is provided. The date tree fiber mix LCM may include includes date tree trunk fibers produced from date tree trunks and date tree leaf and leaf stem fibers produced from date tree leaves and leaf stems. The LCM include a mix of 30% by weight date tree trunk fibers and 70% date tree leaf and leaf stem fibers, 40% by weight date tree trunk fibers and 60% date tree leaf and leaf stem fibers, 50% by weight date tree trunk fibers and 50% date tree leaf and leaf stem fibers. Methods of lost circulation control using and manufacture of a date tree fiber mix LCM are also provided

Analgesic formulations to be applied topically that are reported to relieve moderate to severe pain due to tendonitis, fibromyalgia, shingles, insect bites and bee stings, ACL, arthritis, and sinus headaches. In many cases, test subjects report immediate pain relief with a single application and complete pain elimination with only a few applications. The formulations are in a coconut oil base which is skin friendly. The primary active ingredient is wrightia tinctoria, which when combined with other ingredients, causes the formulation to exhibit a synergistic effect on pain relief unexpected from using the ingredients alone or in combination.

The invention belongs to the technical field of medicament, disclosing an oxycodone controlled release tablet for easing durative moderate to severe pain. The characteristic of the novel formulation is that the invention is controlled release tablet which slowly and constantly or nearly constantly release medicament in water or determined releasing substrate.

The invention relates to an oral pharmaceutical composition comprising the combination of an ibuprofen salt or S(+)-ibuprofen with L-arginine and / or the pharmaceutically acceptable salts thereof, and additionally pharmaceutically acceptable vehicles and / or excipients. The invention also relates to the method of producing the composition and to the use of said composition having synergic therapeutic activity, for treating moderate to severe inflammatory pain, fever and inflammation.